Tag:
VC
Latest Headlines
Latest Headlines
Biotech startup Egalet lassos $14.3M B round, new CEO
Pain med developer Egalet has found a new investor for a second-round financing and hired former Eli Lilly employee Bob Radie as president and CEO.
Early VC rounds nosedive for biotech startups in Q1
After reporting last month that first-quarter venture investing in U.S. biotech dropped by 43%, PWC has drilled deeper into the numbers and noted that young life sciences outfits might have fared even worse than more mature startups.
Amgen, VC groups pump $16.5M into Sutro Biopharma
Skyline Ventures led the second $16.5 million closing of the San Francisco-based startup's Series C round, which included backing from Amgen Ventures, Lilly Ventures, Alta Partners and SV Life Sciences.
Lilly Ventures-backed startup grabs $4.6M round
A secretive startup at Lilly Ventures in Indianapolis has grabbed $4.6 million of a documented $15 million round of equity financing, MedCity News reported, citing SEC documents.
Astellas, biotech VCs to pump $14M into virtual drug developer
Astellas and venture firms Interwest Partners and Sutter Hill Ventures plan to invest $14 million into a startup called Telsar Pharma.
Google VC fuels Series A round for pharma software startup
As major drugmakers spread their R&D bets via a number of partnerships with external groups, Cambridge, MA-based Wingu has raised a Series A round of funding to fuel development of software that...
Third Rock, biotech VCs make baby formula gambit
Some of the usual suspects in biotech venture investing are backing an unusual startup that aims to improve digestion of nutrients in products such as baby formula.
Google VC eyes biotech in data analytics push
Google Ventures, the venture firm backed by Google ($GOOG), is boosting its internal expertise in data analytics and views the life sciences industry as needing Big Data technology to solve some of its sticky research problems.
UPDATED: Tioga nabs $10M VC deal amid PhIII for bowel disorder drug
Tioga Pharmaceuticals has grabbed $10 million in equity for a Series B round as the company funds late-stage development of its key drug for a bowel disorder.
OvaScience grabs $37M B round for fertility treatments
OvaScience, which is focused on developing fertility treatments based on stem cell discoveries, landed a $37 million Series B round of funding.
